S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
NASDAQ:CING

Cingulate (CING) Stock Price, News & Analysis

$0.88
0.00 (0.00%)
(As of 04/19/2024 ET)
Today's Range
$0.83
$0.90
50-Day Range
$0.79
$1.35
52-Week Range
$0.75
$23.80
Volume
175,709 shs
Average Volume
153,199 shs
Market Capitalization
$4.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Cingulate MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
810.0% Upside
$8.00 Price Target
Short Interest
Healthy
1.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.02mentions of Cingulate in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$1,490 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.29 out of 5 stars

CING stock logo

About Cingulate Stock (NASDAQ:CING)

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

CING Stock Price History

CING Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Why you can't focus and what science says can help
Cingulate to Attend DCAT Week 2024 in New York City
See More Headlines
Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/21/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CING
Fax
N/A
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+810.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-23,530,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($5.88) per share

Miscellaneous

Free Float
3,085,000
Market Cap
$4.40 million
Optionable
Not Optionable
Beta
-0.95
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Shane J. Schaffer Pharm.D. (Age 48)
    PharmD, CEO, Principal Financial Officer & Chairman of the Board
    Comp: $491.96k
  • Dr. Laurie A. Myers M.B.A. (Age 66)
    Ph.D., Executive VP & COO
    Comp: $415.17k
  • Dr. Matthew N. Brams M.D. (Age 59)
    Executive VP & Chief Medical Officer
    Comp: $244.79k
  • Ms. Jennifer L. Callahan CPA (Age 53)
    CFO, Senior VP & Corporate Controller
  • Dr. Raul R. Silva M.D. (Age 65)
    Executive VP & Chief Science Officer
  • Thomas Dalton
    Head of Investor & Public Relations

CING Stock Analysis - Frequently Asked Questions

Should I buy or sell Cingulate stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CING shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CING, but not buy additional shares or sell existing shares.
View CING analyst ratings
or view top-rated stocks.

What is Cingulate's stock price target for 2024?

3 analysts have issued 1-year price objectives for Cingulate's shares. Their CING share price targets range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 810.0% from the stock's current price.
View analysts price targets for CING
or view top-rated stocks among Wall Street analysts.

How have CING shares performed in 2024?

Cingulate's stock was trading at $7.65 at the beginning of 2024. Since then, CING shares have decreased by 88.5% and is now trading at $0.8791.
View the best growth stocks for 2024 here
.

When is Cingulate's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CING earnings forecast
.

When did Cingulate's stock split?

Cingulate's stock reverse split on the morning of Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Cingulate IPO?

Cingulate (CING) raised $29 million in an IPO on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share.

How do I buy shares of Cingulate?

Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CING) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners